BT Test for Breast Cancer Now Covered by Insurance

Women pay no out-of-pocket cost for Provista Life Sciences'
groundbreaking early breast cancer detection test
PHOENIX--(Business Wire)--
Provista Life Sciences LLC (PLS) today announced it will file
private insurance claims on behalf of women who take the BT Test(TM)
and cover 100 percent of the test's cost not covered by insurance. The
BT Test is a blood test that assists in the early detection of breast
cancer. For women who do not wish to submit an insurance claim, the BT
Test is now available at a cost of $295.

"We have early indication from private insurance companies that
they are able to cover the cost of the BT Test, making it even more
accessible to women who previously had to pay out-of-pocket for the
test," said Joel Bird, Vice President of Reimbursement Strategies at
Provista Life Sciences.

The BT Test, or Biomarker Translation Test, is prescribed by
physicians and is used in conjunction with an annual mammogram to
assist in making an earlier and more accurate diagnosis of breast
cancer. The BT Test finds multiple cancer-related proteins in the
blood and combines the results with the patient's medical profile to
help physicians find breast cancer as early as possible. When detected
early, breast cancer has a 96 percent survival rate.

"With an accuracy rate above 80 percent, the BT Test gives women
and their doctors another crucial measure for early breast cancer
detection," said Will Gartner, President and CEO at Provista Life
Sciences. "We are thrilled to be able to offer more women the
opportunity to catch the disease in its treatable phase, when
life-saving treatment is most effective."

According to the American Cancer Society, women over the age of
40, especially those at higher risk for breast cancer, should be
screened for breast cancer annually. The BT Test is available to all
women ages 35 to 75, and is strongly recommended by many gynecologists
and breast surgeons for women at heightened risk for breast cancer and
those under age 50 whose breast density can make it more difficult for
a mammogram to detect the presence of cancer.

The BT Test requires a simple blood draw that is sent to Provista
Diagnostics, a CLIA (Clinical Laboratory Improvement Amendments)
registered Reference Laboratory, and a wholly owned subsidiary of
Provista Life Sciences, to be analyzed. The results of the breast
cancer test are then sent to the prescribing physician to review with
the patient.

Provista Life Sciences is currently working with physicians in
Arizona to offer the BT Test as part of a comprehensive annual breast
health examination and anticipates making the test available to
additional markets in 2008. Healthcare providers and women interested
in learning more about the BT Test can call 602-224-5500.

About Provista Life Sciences

Provista Life Sciences is a biotechnology diagnostics development
and commercialization organization that provides the scientific and
operating management resources to rapidly advance the development and
introduction of novel diagnostics technologies into the domestic and
global marketplace. For more information, visit the company's Web site
at www.ProvistaLS.com or call 602-224-5500.

for Provista Life Sciences
Carol Klimas, 480-505-4527
carolk@offmadisonave.com
www.ProvistaLS.com

Copyright Business Wire 2008